Archive: 11/12/2018
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn's disease
A biosimilar of infliximab, CT-P13, has equivalent safety and efficacy to that of the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn's disease in infliximab-naïve patients. Findings from a comparative ...
Dec 11, 2018